Abstracts tagged "Bisphosphonates"

Abstract Number: 1875 • 2019 ACR/ARP Annual Meeting
Subject Characteristics and Changes in Bone Mineral Density After Transitioning from Denosumab to Alendronate in the Denosumab Adherence Preference Satisfaction (DAPS) Study
David Kendler¹, Arkadi Chines ², Patricia Clark ³, Peter R. Ebeling ⁴, Michael McClung ⁵, Yumie Rhee ⁶, Shuang Huang ², Robert Kees Stad ⁷ and Nick Freemantle ⁸, ¹University of British Columbia, Vancouver, BC, Canada, ²Amgen Inc., Thousand Oaks, CA, ³Hospital Infantil de Mexico Federico Gómez and National University of Mexico, Mexico City, Mexico, ⁴Monash University, Melbourne, Victoria, Australia, ⁵Oregon Osteoporosis Center, Portland, OR, ⁶Yonsei University College of Medicine, Seoul, Republic of Korea, ⁷Amgen Inc., Rotkreuz, Zug, Switzerland, ⁸University College London, London, England, United Kingdom
Background/Purpose: There are limited data on patients transitioning from denosumab (DMAb) to bisphosphonates (BPs). The Denosumab Adherence Preference Satisfaction (DAPS) study (NCT00518531) reported that alendronate…
Abstract Number: 2657 • 2019 ACR/ARP Annual Meeting
The Association Between Bisphosphonates and Giant Cell Arteritis: A Retrospective Cohort Study
Salman Mahmood¹, Yuanyuan Ji ², Yi Peng ² and Zaki Abou Zahr ¹, ¹Hennepin Healthcare, Minneapolis, MN, ²Chronic Disease Research Group, Hennepin Healthcare Research Institute, Minneapolis, MN
Background/Purpose: Bisphosphonates have been used to treat disorders of bone metabolism for several years. A common adverse reaction associated with their use constitutes a transient…
Abstract Number: 293 • 2018 ACR/ARHP Annual Meeting
Temporal Trends and Factors Associated with Bisphosphonate Drug Holidays
Jeffrey R. Curtis¹, Rui Chen¹, Tarun Arora¹, Shanette Daigle¹, Robert Matthews¹, Huifeng Yun¹, Nicole Wright², Ayesha Jaleel³, Elizabeth Delzell⁴ and Kenneth Saag⁵, ¹University of Alabama at Birmingham, Birmingham, AL, ²Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ³University of Alabama at Birmingham, Birmngham, AL, ⁴Retired - University of Alabama at Birmingham, Birmingham, AL, ⁵UAB, Birmingham, AL
Background/Purpose: Safety concerns related to osteoporosis (OP) medication use and temporary or permanent cessation of bisphosphonate therapy (e.g. ‘drug holidays’) have generated appreciable attention in…
Abstract Number: 1256 • 2018 ACR/ARHP Annual Meeting
A Customized Health Information Technology Effectively Identifies and Directs Bone Health Services in Rural Veterans with Osteoporosis Risk Factors
Shardool Patel¹, Zachary L. Anderson¹, Grant W. Cannon², Brian C. Sauer² and Karla L. Miller², ¹Salt Lake City VA Medical Center, Salt Lake City, UT, ²Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT
Background/Purpose: Osteoporosis is underdiagnosed and undertreated in the Veterans Health Administration (VHA), especially in rural Veterans. Tools to identify risk factors in Veterans are available.…
Abstract Number: 1818 • 2018 ACR/ARHP Annual Meeting
Greater BMD Gains with Denosumab Vs Risedronate in Glucocorticoid-Treated Subjects: Results from the Final 24-Month Analysis of a Randomized, Double-Blind, Double-Dummy Study
Kenneth Saag¹, Nicola Pannacciulli², Piet Geusens³, Jonathan D. Adachi⁴, Osvaldo D. Messina⁵, Jorge Morales-Torres⁶, Ronald Emkey⁷, Peter W. Butler², Xiang Yin² and Willem F. Lems⁸, ¹University of Alabama at Birmingham, Birmingham, AL, ²Amgen Inc., Thousand Oaks, CA, ³Maastricht University, Maastricht, Netherlands, ⁴McMaster University, Hamilton, ON, Canada, ⁵Cosme Argerich Hospital, Buenos Aries, Argentina, ⁶Hospital Aranda de la Parra, Leon, Mexico, ⁷Emkey Arthritis & Osteoporosis Clinic, Wyomissing, PA, ⁸VU University Medical Centre, Amsterdam, Netherlands
Background/Purpose: Denosumab 60 mg subcutaneously every 6 months (Q6M) increased spine and hip BMD significantly more than risedronate 5 mg orally once daily (QD) at…
Abstract Number: 2299 • 2018 ACR/ARHP Annual Meeting
Subgroup Analysis of the Effect of Denosumab Compared with Risedronate on Percentage Change in Lumbar Spine Bone Mineral Density at 24 Months in Glucocorticoid-Treated Individuals
Kenneth Saag¹, Nicola Pannacciulli², Piet Geusens³, Jonathan D. Adachi⁴, Eric Lespessailles⁵, Jorge Malouf⁶, Bente Langdahl⁷, Peter W. Butler², Xiang Yin² and Willem F. Lems⁸, ¹University of Alabama, Birmingham, AL, ²Amgen Inc., Thousand Oaks, CA, ³Maastricht University, Maastricht, Netherlands, ⁴McMaster University, Hamilton, ON, Canada, ⁵University Hospital Orleans, Orleans, France, ⁶Hospital San Pablo, Barcelona, Spain, ⁷Aarhus University, Aarhus, Denmark, ⁸VU University Medical Centre, Amsterdam, Netherlands
Background/Purpose: We previously demonstrated that denosumab increased lumbar spine and total hip bone mineral density (BMD) significantly more than risedronate at 12 and 24 months…
Abstract Number: 2808 • 2018 ACR/ARHP Annual Meeting
T-Score As an Indicator of Fracture Risk on Therapy: Evidence from Romosozumab Vs Alendronate Treatment in the Active-Controlled Fracture Study in Postmenopausal Women with Osteoporosis at High Risk Trial
Felicia Cosman¹, E. Michael Lewiecki², Peter R Ebeling³, Eric Hesse⁴, Nicola Napoli⁵, Daria B Crittenden⁶, Maria Rojeski⁶, Wenjing Yang⁶, Cesar Libanati⁷ and Serge Ferrari⁸, ¹Columbia University, New York, NY, ²New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, ³Monash University, Melbourne, Australia, ⁴University Medical Center Hamburg-Eppendorf, Hamburg, Germany, ⁵Campus Bio-Medico University of Rome, Rome, Italy, ⁶Amgen Inc., Thousand Oaks, CA, ⁷UCB Pharma, Brussels, Belgium, ⁸Geneva University Hospital, Geneva, Switzerland
Background/Purpose: BMD is a strong predictor of fracture risk in untreated patients. Recent evidence suggests that BMD achieved during treatment also reflects fracture risk; thus,…
Abstract Number: 2812 • 2018 ACR/ARHP Annual Meeting
Evaluation of Cortical Microarchitecture, Bone Stiffness and Bone Remodeling in Patients with Atypical Femoral Fracture
Mariana O Perez¹, Diogo S Domiciano¹, Luciene M Reis², Vanda Jorgetti² and Rosa M R Pereira¹, ¹Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil, ²Nephrology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil
Background/Purpose: Atypical femoral fractures (AFF) are low energy femoral fractures and subtrochanteric/diaphyseal localization that have been related to long-term bisphosphonate therapy. Patients with AFF exhibit…
Abstract Number: 333 • 2017 ACR/ARHP Annual Meeting
Atypical Femoral Fracture in Patients of a Rheumatology Service: Clinical, Radiographic and Bone Histomorphometric Data
Mariana O Perez¹, Diogo S Domiciano¹, Vanda Jorgetti² and Rosa M R Pereira¹, ¹Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil, ²Nephrology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil
Background/Purpose: Atypical femoral fractures (AFF) are low energy femoral fractures with a specific radiographic pattern and subtrochanteric / diaphyseal localization that have been related to…
Abstract Number: 828 • 2017 ACR/ARHP Annual Meeting
The Impact of the Duration of Bisphosphonate Drug Holidays on Hip Fracture Rates
Jeffrey R. Curtis¹, Rui Chen², Zixu (Eric) Li², Tarun Arora², Kenneth Saag³, Nicole C. Wright⁴, Shanette Daigle², Meredith Kilgore⁵ and Elizabeth Delzell⁶, ¹Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³Department of Medicine, Veterans Administration San Diego Healthcare System/UC San Diego, San Diego, CA, ⁴Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁵Health Care Organization & Policy, University of Alabama at Birmingham, Birmingham, AL, ⁶Retired - University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Given FDA warnings, drug holidays (temporary or permanent discontinuation) of bisphosphonates (BPs) after long-term (3-5 years) continuous therapy is becoming increasingly common in the…
Abstract Number: 839 • 2017 ACR/ARHP Annual Meeting
Use of Bisphosphonate and Risk of Incident Atrial Fibrillation in a Population-Based Study
Shanshan Sheehy¹, Christine Peloquin² and Tuhina Neogi³, ¹Clinical Epidemiology Research & Training Unit, Boston University, Boston, MA, ²Boston University School of Medicine, Boston, MA, ³Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA
Background/Purpose: Bisphosphonates remain the first-line agent prescribed medication for the prevention and treatment of osteoporosis. Apart from concern about atypical fractures, another concern about risk…
Abstract Number: 1194 • 2017 ACR/ARHP Annual Meeting
Are Bisphosphonates Efficacious in Knee Osteoarthritis? A Meta-Analysis of Randomized Controlled Trials
Mikala C. Osani¹, Elizaveta Vaysbrot¹, Raveendhara R. Bannuru², Mia-Cara Musetti¹ and Timothy E. McAlindon¹, ¹Division of Rheumatology, Tufts Medical Center, Boston, MA, ²Center of Integrative Medicine and Division of Rheumatology, Tufts Medical Center, Boston, MA, Boston, MA
Background/Purpose: One of the key aspects of osteoarthritis (OA) pathogenesis is subchondral bone remodeling. Bisphosphonates have been touted as disease-modifying agents for OA due to…
Abstract Number: 1212 • 2017 ACR/ARHP Annual Meeting
Relation of Incident Bisphosphonate Use to Bone Marrow Lesion Volume in Knee Osteoarthritis
Tuhina Neogi¹, Jeffrey Duryea², Na Lu¹, Jingbo Niu¹ and Yuqing Zhang¹, ¹Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA, ²Radiology, Brigham & Women's Hospital/ Harvard Medical School, Boston, MA
Background/Purpose: Bone marrow lesions (BMLs) are important contributors to pain and progression of knee OA. There has been recent interest in bisphosphonates as a potential…
Abstract Number: 1228 • 2017 ACR/ARHP Annual Meeting
Postmenopausal Breast Cancer Patients on Aromatase Inhibitor Therapy and Their Increased Risk of Fragility Fracture
Anna Lafian¹, Julia Suh² and Karina Torralba³, ¹Internal Medicine, Arrowhead Regional Medical Center, Colton, CA, ²Internal Medicine, Loma Linda University, Loma Linda, CA, ³Internal Medicine/Rheumatology, Loma Linda University, Loma Linda, CA
Background/Purpose: Postmenopausal women with breast cancer have higher osteoporosis risk due to declining estrogen levels and use of aromatase inhibitors (AIs). The American Society of…
Abstract Number: 1850 • 2017 ACR/ARHP Annual Meeting
Efficacy of Zoledronic Acid and Denosumab in the Treatment of Patients with Low Back Pain and Modic Changes: A Proof of Principle Trial
Guoqi Cai¹, Laura Laslett¹, Dawn Aitken², Andrew Halliday³, Feng Pan², Petr Otahal¹, Deb Speden⁴, Tania Winzenberg¹ and Graeme Jones², ¹Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia, ²Musculoskeletal Unit, Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia, ³Radiology, Royal Hobart Hospital, Hobart, Australia, ⁴Royal Hobart Hospital, Hobart, Australia
Background/Purpose: Low back pain (LBP) is a common and debilitating problem. There are currently very limited pharmacological treatments for LBP. Vertebral endplate subchondral bone abnormalities…